1. Research
  2. Publications

Publications

Export 36 results:
Filters: Author is Marie-France Demers  [Clear All Filters]
2023
“Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review.”, J Psychopharmacol, vol. 37, no. 4, pp. 370-377, 2023.
“Gaming Disorder and Psychotic Disorders: A Scoping Review.”, Psychopathology, vol. 56, no. 4, pp. 315-323, 2023.
“Problem gambling among people with first-episode psychosis: protocol for a prospective multicenter cohort study.”, BMC Psychiatry, vol. 23, no. 1, p. 287, 2023.
“Sex-specific immune mechanisms in PTSD symptomatology and risk: A translational overview and perspectives.”, Brain Res Bull, vol. 195, pp. 120-129, 2023.
2022
S. Brodeur, Vanasse, A., Courteau, J., Courteau, M., Stip, E., Fleury, M. ‐J., Lesage, A., Demers, M. - F., and Roy, M. ‐A., “Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: A state sequence analysis approach”, Acta Psychiatrica Scandinavica, vol. 145, no. 5, pp. 469 - 480, 2022.
“Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: A state sequence analysis approach.”, Acta Psychiatr Scand, vol. 145, no. 5, pp. 469-480, 2022.
“Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study.”, Br J Psychiatry, pp. 1-8, 2022.
“Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations.”, Clin Psychopharmacol Neurosci, vol. 20, no. 1, pp. 194-198, 2022.
“Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation.”, Ther Adv Psychopharmacol, vol. 12, p. 20451253221136021, 2022.
2021
L. - D. Leclerc, Demers, M. - F., Bardell, A., Bilodeau, I., Williams, R., Tibbo, P., and M-A Roy, “A Chart Audit Study of Clozapine Utilization in Early Psychosis.”, J Clin Psychopharmacol, vol. 41, no. 3, pp. 275-280, 2021.
L. Béchard, Corbeil, O., Plante, M., Thivierge, M. - A., Lafrenière, C. - É., M-A Roy, and Demers, M. - F., “Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series.”, J Psychopharmacol, vol. 35, no. 9, pp. 1152-1157, 2021.
O. Corbeil, Corbeil, S., Dorval, M., Carmichael, P. - H., Giroux, I., Jacques, C., Demers, M. - F., and M-A Roy, “Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program.”, CNS Drugs, vol. 35, no. 4, pp. 461-468, 2021.
“[Psychopharmacology of First Episode Psychosis: An Approach Based on Recovery].”, Sante Ment Que, vol. 46, no. 2, pp. 113-137, 2021.
2020
M. - A. Nolin, Demers, M. - F., Rauzier, C., Bouchard, R. - H., Cadrin, C., Després, J. - P., M-A Roy, Alméras, N., and Picard, F., “Circulating IGFBP-2 levels reveal atherogenic metabolic risk in schizophrenic patients using atypical antipsychotics.”, World J Biol Psychiatry, pp. 1-8, 2020.
O. Corbeil, Corbeil, S., Giroux, I., Jacques, C., Dorval, M., Demers, M. - F., and M-A Roy, “Problem Gambling Associated With Aripiprazole in First-Episode Psychosis Patients: A Series of 6 Case Reports.”, J Clin Psychopharmacol, vol. 40, no. 2, pp. 191-194, 2020.
V. Ferraro, Lafrenière, S., Demers, M. - F., M-A Roy, and Abdel-Baki, A., “"Real world" clinical effectiveness of paliperidone palmitate 3-monthly injectable in early psychosis patients.”, Psychopharmacology (Berl), 2020.
2019
A. Lachance, Corbeil, O., Corbeil, S., Chalifour, G., Breault, A. - S., M-A Roy, and Demers, M. - F., “Case Reports of Aripiprazole and Problematic Gambling in Schizophrenia: A Critical Review of the Evidence.”, J Clin Psychopharmacol, vol. 39, no. 4, pp. 393-397, 2019.
2018
M. - F. Demers, Fortier, L., Corbeil, O., Breault, A. - S., and M-A Roy, “Continuing clozapine despite recurrent neutropenia: A 8 year follow-up case report with granulocyte-colony stimulating factor as-required use.”, Asian J Psychiatr, 2018.
M-A Roy, Vallières, C., Lehoux, C., Leclerc, L. - D., Demers, M. - F., and Achim, A., “More intensive probing increases the detection of social anxiety disorders in schizophrenia.”, Psychiatry Res, vol. 268, pp. 358-360, 2018.
M-A Roy, Demers, M. - F., and Achim, A., “Social anxiety disorder in schizophrenia: a neglected, yet potentially important comorbidity.”, J Psychiatry Neurosci, vol. 43, no. 4, pp. 287-288, 2018.
2017
J. - D. Carrier, Blais, L., Cohen, A., Courteau, J., Roberge, P., Larouche, A., Grignon, S., Fleury, M. - J., Lesage, A., Demers, M. - F., M-A Roy, Delorme, A., and Vanasse, A., “[Initiating an antipsychotic drug treatment for schizophrenia: the situation in Quebec, Canada, from 1998 to 2006].”, Sante Ment Que, vol. 42, no. 1, pp. 85-103, 2017.
P. D. Vincent, Demers, M. - F., Doyon-Kemp, V., Duchesneau, J., Halme, A., and Masson, V., “One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada.”, Schizophr Res, vol. 185, pp. 96-100, 2017.
2016
A. Vanasse, Blais, L., Courteau, J., Cohen, A. A., Roberge, P., Larouche, A., Grignon, S., Fleury, M. - J., Lesage, A., Demers, M. - F., M-A Roy, Carrier, J. - D., and Delorme, A., “Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study.”, Acta Psychiatr Scand, vol. 134, no. 5, pp. 374-384, 2016.
2015
M-A Roy, Achim, A., Vallières, C., Labbé, A., Mérette, C., Maziade, M., Demers, M. - F., and Bouchard, R. - H., “Comorbidity between anxiety disorders and recent-onset psychotic disorders.”, Schizophr Res, vol. 166, no. 1-3, pp. 353-4, 2015.
2008
S. Potvin, Stip, E., Lipp, O., M-A Roy, Demers, M. - F., Bouchard, R. - H., and Gendron, A., “Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.”, Am J Drug Alcohol Abuse, vol. 34, no. 1, pp. 75-82, 2008.

Funding / Support / Partners

logo FRQ-S logo ctrn logo fci logo cihr irsc logo nserc logo MESISentinelle nord